Invivo Therapeutics (NASDAQ: NVIV) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.
Volatility and Risk
Invivo Therapeutics has a beta of 3.21, indicating that its share price is 221% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
12.8% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of LeMaitre Vascular shares are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by company insiders. Comparatively, 23.7% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Invivo Therapeutics and LeMaitre Vascular’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.7%. Invivo Therapeutics does not pay a dividend. LeMaitre Vascular pays out 28.2% of its earnings in the form of a dividend.
Valuation and Earnings
This table compares Invivo Therapeutics and LeMaitre Vascular’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Invivo Therapeutics||N/A||N/A||-$23.43 million||($0.85)||-0.84|
|LeMaitre Vascular||$89.15 million||6.90||$10.59 million||$0.78||40.97|
LeMaitre Vascular has higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and recommmendations for Invivo Therapeutics and LeMaitre Vascular, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Invivo Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 745.07%. LeMaitre Vascular has a consensus target price of $31.50, suggesting a potential downside of 1.44%. Given Invivo Therapeutics’ higher probable upside, equities research analysts plainly believe Invivo Therapeutics is more favorable than LeMaitre Vascular.
LeMaitre Vascular beats Invivo Therapeutics on 12 of the 15 factors compared between the two stocks.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.